EC
CGEM icon

EntryPoint Capital’s Cullinan Oncology CGEM Stock Holding History

EntryPoint Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Buy
+11,556
New +$172K 0.05% 678
2026
Q1 		– Sell
-23,788
Closed -$246K – 770
2025
Q4 		$246K Sell
23,788
-18,402
-44% -$166K 0.1% 446
2025
Q3 		$250K Buy
42,190
+31,072
+279% +$228K 0.1% 453
2025
Q2 		$83.7K Sell
11,118
-13,072
-54% -$105K 0.04% 572
2025
Q1 		$183K Buy
24,190
+9,533
+65% +$91.5K 0.08% 557
2024
Q4 		$179K Buy
+14,657
New +$211K 0.08% 611

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

EntryPoint Capital's CGEM Position: Q2 2026 in Review

EntryPoint Capital opened a new position in Cullinan Oncology (CGEM) in Q2 2026: 11,556 shares worth $210K. The stake represents 0.05% of the portfolio and ranks #678 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in CGEM as recently as Q4 2025.

EntryPoint Capital first reported a position in CGEM in Q4 2024 and has held it in 6 quarters since. The position peaked at $250K in Q3 2025. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • EntryPoint Capital held 11,556 shares of Cullinan Oncology worth $210K as of Q2 2026.
  • Cullinan Oncology was a new EntryPoint Capital position in Q2 2026.
  • Cullinan Oncology made up 0.05% of EntryPoint Capital's portfolio in Q2 2026, its #678 holding.
  • EntryPoint Capital first reported a position in Cullinan Oncology in Q4 2024 and has held it in 6 quarters since.
  • EntryPoint Capital's Cullinan Oncology position peaked at $250K in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.